---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110862"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:34:07.151217+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics announces CNTY-813 T1D program; Q3 net loss $34.4M, cash $132.7M

## Summary
- CNTY-813 is iPSC-derived beta islet therapy for T1D; preclinical data show reversal of diabetes in mouse models.
- IND-enabling studies for CNTY-813 to start by year-end 2025; IND submission planned as early as 2026.
- Q3 2025 net loss $34.4M vs $31.2M in Q3 2024; R&D expenses down to $22.5M from $27.2M.
- Cash and investments $132.7M as of Sep 30, 2025; estimated cash runway into Q4 2027.
- Discontinuing company-sponsored CALiPSO-1 trial; continuing CARAMEL IST with data expected Dec 5, 2025.

## SEC filing metadata
- accession: 0001104659-25-110862
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465925110862/0001104659-25-110862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465925110862/tm2530897d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110862
- JSON: https://secwatch.observer/filing/0001104659-25-110862.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.